Snapshot from Jul 20, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Appili Therapeutics VXV-01 Contract...
Regulatory contract termination

Appili Therapeutics VXV-01 Contract Terminated

Analysis based on 7 articles · First reported Jul 03, 2026 · Last updated Jul 04, 2026

Sentiment
-60
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The termination of the contract by the Norway — Norwegian Institute of Public Health for the VXV-01 program is a significant negative for Appili Therapeutics, potentially impacting its stock price due to the loss of US$3.6 million in funding. Investors may view this as a setback for Appili Therapeutics's pipeline and future revenue, despite the company's focus on other assets like ATI-1801 and LIKMEZ®.

biopharmaceutical
Event Summary

Appili Therapeutics Inc. announced that it received a Notice of Termination for Convenience from the Norway — Norwegian Institute of Public Health, a part of the United States — National Institutes of Health. This notice relates to contract number 75N93025C00033, which was awarded in October 2025 to support the development of the VXV-01 fungal vaccine candidate. The contract had a 22-month base period of performance totaling US$3.6 million. Appili Therapeutics is currently evaluating the implications of this termination. The company stated it will now focus on maximizing value from its ATI-1801 program and continue to benefit from royalty revenue generated by LIKMEZ®.

Key Actions
100 Norway — Norwegian Institute of Public Health issued notice of termination Appili Therapeutics
Entities Involved
stock
Appili Therapeutics
Appili Therapeutics received a termination notice for a significant contract, impacting its VXV-01 fungal vaccine candidate program and potentially its financial outlook. The company is assessing the implications and focusing on other assets like ATI-1801 and LIKMEZ®.
Importance 100.0 Sentiment -70.0
oth
VXV-01
VXV-01, a fungal vaccine candidate, is the subject of the terminated contract, halting its development under the Norway — Norwegian Institute of Public Health funding.
Importance 90.0 Sentiment -80.0
govactor
Norway — Norwegian Institute of Public Health
The Norway — Norwegian Institute of Public Health issued a Notice of Termination for Convenience for its contract with Appili Therapeutics, ceasing funding for the VXV-01 program.
Importance 80.0 Sentiment 0.0
oth
ATI-1801
ATI-1801 is a Priority Review Voucher eligible program targeting cutaneous leishmaniasis that Appili Therapeutics is now focusing on to maximize value after the contract termination.
Importance 70.0 Sentiment 20.0
govactor
United States — National Institutes of Health
The United States — National Institutes of Health, as the parent organization of the Norway — Norwegian Institute of Public Health, is indirectly involved in the contract termination with Appili Therapeutics.
Importance 60.0 Sentiment 0.0
oth
LIKMEZ
LIKMEZ® generates royalty revenue for Appili Therapeutics, providing a source of sustainable revenue amidst the contract termination.
Importance 50.0 Sentiment 10.0
Relationships
Norway — Norwegian Institute of Public Health related ↔ United States — National Institutes of Health
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.